

Material Safety Data Sheet

"DIMENSION" CLINICAL CHEMISTRY SYSTEM CTNI FLEX(TM) REAGENT CARTRIDGE
RADM0021
Revised: 04/19/2002

CHEMICAL PRODUCT/COMPANY IDENTIFICATION

Tradenames and Synonyms

CAT. NO. RF421A,B,C/RF521
CTNI FLEX(TM) REAGENT CARTRIDGE
"DIMENSION" CTNI FLEX(TM) REAGENT CARTRIDGE
CARDIAC TROPONIN I FLEX
LTNI FLEX(TM)
TROPONIN Flex(TM) for Xpand

Company Identification

MANUFACTURER/DISTRIBUTOR
Dade Behring Inc.
P. O. Box 6101
Newark, DE 19714-6101

PHONE NUMBERS

Product Information : 800-441-9250
Transport Emergency : CHEMTREC 800-424-9300
Medical Emergency : 800-228-5635 ext 284

COMPOSITION/INFORMATION ON INGREDIENTS

Components

| Material | CAS Number | % |
|-------------------------|------------|--------|
| RxL CTNI Chrome Tablet | | |
| Polyethylene Glycol | 25322-68-3 | 7.31 |
| Trehalose | 99-20-7 | 81.62 |
| Chrome Particle Reagent | | 10.24 |
| Glutaraldehyde | 111-30-8 | 0.01 |
| Streptomycin sulphate | 3810-74-0 | <0.001 |
| RxL FADP Tablet | | |
| Trehalose | 99-20-7 | 41.89 |
| Polyethylene Glycol | 25322-68-3 | 7.82 |
| d-Proline | 344-25-2 | 40.58 |

| | | |
|---|------------|-------|
| Bicine | 150-25-4 | 9.67 |
| APO Tablet | | |
| Trehalose | 99-20-7 | 48 |
| Polyethylene Glycol | 25322-68-3 | 9.1 |
| DCHBS | 54970-72-8 | 6.6 |
| 4-Aminoantipyrine | 83-07-8 | 1.58 |
| Bicine | 150-25-4 | 32.94 |
| RxL CTNI Conjugate Reagent | | |
| Sodium Chloride | 7647-14-5 | 2.75 |
| Bovine Serum Albumin | 9048-46-8 | 3.12 |
| PIPES | 5625-37-6 | 5.43 |
| StabilZyme(R) exact identity trade secret | | 50 |
| Water | 7732-18-5 | 37.71 |
| Cascade Diluent | | |
| Water | 7732-18-5 | 96.51 |
| Bicine | 150-25-4 | 3.21 |
| 2-Chloroacetamide | 79-07-2 | 0.1 |
| Sodium azide | 26628-22-8 | 0.095 |
| Streptomycin sulphate | 3810-74-0 | 0.03 |
| CTNI Chrome Diluent | | |
| Water | 7732-18-5 | 82.88 |
| Bovine Serum Albumin | 9048-46-8 | 5 |
| Sodium Chloride | 7647-14-5 | 10.24 |

WARNING: These reagents contain sodium azide. Sodium azide may react with lead or copper plumbing to form highly explosive metal azides. If discarded into drain, flush with a large volume of water to prevent azide build-up.

HAZARDS IDENTIFICATION

Potential Health Effects

Since this mixture has not been tested as a whole to determine the hazards by all routes of exposure, information is provided for each hazardous component of the mixture to meet requirements of OSHA's Hazard Communication Standard (29 CFR 1910.1200). The effects noted occur from exposure to the pure component unless otherwise noted.

INFORMATION FOR COMPONENTS

SODIUM CHLORIDE is an IRRITANT. Human health effects of overexposure by inhalation, ingestion, or skin or eye

contact may cause nonspecific discomfort, such as nausea, headache, or weakness upon ingestion; or eye irritation with tearing, or blurring of vision on eye contact.

POLYETHYLENE GLYCOL is not expected to cause significant acute effects from modest overexposure. Higher exposures to some lower molecular weight materials may lead to abnormal liver or kidney function as detected by laboratory tests. This product contains no lower molecular weight material.

CHROME PARTICLE REAGENT contains chromium (IV) dioxide which is a skin and eye irritant. Skin contact may initially include irritation with discomfort or rash. Eye contact may initially include irritation with discomfort, tearing or blurring of vision. Chronic overexposure by inhalation to the dust may cause respiratory irritation with scarring and abnormal tissue structure of the lungs.

BICINE is harmful if ingested, inhaled, or absorbed through the skin; causes eye and skin irritation; chemical, physical and toxicological properties have not been thoroughly investigated.

4-AMINO ANTIPYRINE (4AAP) may be irritating to skin and eye on contact. Other agents in this class are known to cause mental disturbances, cyanosis, nausea and vomiting.

2-CHLOROACETAMIDE and GLUTARALDEHYDE are sensitizers. Toxic effects include contact dermatitis, allergic contact eczema and respiratory allergy symptoms.

SODIUM AZIDE is not likely to be a human health hazard in the amount present in this product. However, lowering the pH of azide solution below 6 may generate very irritating hydrazoic acid gas which is a skin and eye irritant and can cause headaches even in very small quantities.

Carcinogenicity Information

None of the components present in this material at concentrations equal to or greater than 0.1% are listed by IARC, NTP, OSHA or ACGIH as a carcinogen.

FIRST AID MEASURES

First Aid

INHALATION

Inhalation is not an expected route of exposure during normal use of the product.

SKIN CONTACT

Flush skin with water after contact. Wash contaminated clothing before reuse.

EYE CONTACT

In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Call a physician.

INGESTION

Ingestion is not an expected route of exposure during normal use of the product. If ingested, consult a physician.

FIRE FIGHTING MEASURES

Extinguishing Media

Use media appropriate for surrounding material.

Fire Fighting Instructions

Evacuate personnel to a safe area. Keep personnel removed and upwind of fire. Wear self-contained breathing apparatus. Wear full protective equipment.

ACCIDENTAL RELEASE MEASURES

Safeguards (Personnel)

NOTE: Review FIRE FIGHTING MEASURES and HANDLING (PERSONNEL) sections before proceeding with clean-up. Use appropriate PERSONAL PROTECTIVE EQUIPMENT during clean-up.

Initial Containment

Follow applicable Federal, State/Provincial and Local laws/regulations.

HANDLING AND STORAGE

Handling (Personnel)

Do not breathe vapor or mist. Avoid contact with eyes, skin, or clothing. Wash thoroughly after handling. Do not store or consume food, drink or tobacco in areas where they may become contaminated with this material.

Storage

See package/insert sheet.

EXPOSURE CONTROLS/PERSONAL PROTECTION

Personal Protective Equipment

Eye/Face : safety glasses
Protective Gloves : nitrile or similar

Exposure Guidelines

Applicable Exposure Limits

Sodium Azide
PEL (OSHA) : None Established
TLV (ACGIH) : Ceiling 0.29 ppm, A4
as Hydrazoic acid vapor
Ceiling: 0.11 mg/m³, A4

Glutaraldehyde
PEL (OSHA) : None Established
TLV (ACGIH) : Ceiling 0.05 ppm, 0.2 mg/m³
SEN, A4

PHYSICAL AND CHEMICAL PROPERTIES

Physical Data

A self-contained cartridge with liquid in wells 5, 7, and 8; tablets in wells 1, 2, and 4.

STABILITY AND REACTIVITY

Chemical Stability

Stable at normal conditions.

Decomposition

Decomposes with heat.

Hazardous gases/vapors produced are carbon oxides, nitrogen oxides and phosphorous oxides.

Polymerization

Polymerization will not occur.

DISPOSAL CONSIDERATIONS

Waste Disposal

Treatment, storage, transportation, and disposal must be in accordance with applicable Federal, State/Provincial, and Local regulations.

Chromium (IV) dioxide is present in this product. The reagents containing chrome have been tested following the Environmental Protection Agency TCLP protocol and found not to be a hazardous waste. However, when this product is used with human source sample material, disposal must follow all guidelines for infectious waste.

REGULATORY INFORMATION

State Regulations (U.S.)

WARNING - SUBSTANCES KNOWN TO THE STATE OF CALIFORNIA TO CAUSE CANCER, BIRTH DEFECTS OR OTHER REPRODUCTIVE HARM- Streptomycin sulfate

OTHER INFORMATION

"DIMENSION" is a trademark of Dade Behring Inc.

StabilZyme is a registered trademark of the BSI Corporation.

The data in this Material Safety Data Sheet relates only to the specific material designated herein and does not relate to use in combination with any other material or in any process.

Technical Assistance Center
Dade Behring Inc.
Newark, DE 19714-6101
1-800-441-9250

End of MSDS